Page last updated: 2024-11-02
pioglitazone and Co-infection
pioglitazone has been researched along with Co-infection in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Pioglitazone was well tolerated and no one discontinued due to side effects." | 6.80 | Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015) |
| "Pioglitazone was well tolerated and no one discontinued due to side effects." | 2.80 | Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Matthews, L | 1 |
| Kleiner, DE | 1 |
| Chairez, C | 1 |
| McManus, M | 1 |
| Nettles, MJ | 1 |
| Zemanick, K | 1 |
| Morse, CG | 1 |
| Benator, D | 1 |
| Kovacs, JA | 1 |
| Hadigan, C | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection[NCT00742326] | Phase 4 | 13 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Enrollment stopped prior to complete enrollment due to slow accrual) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.
Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline (NCT00742326)
Timeframe: 48 weeks
| Intervention | percentage of hepatic fat on MRS (Mean) |
|---|
| Pioglitazone | -7.43 |
| Placebo | -2.17 |
Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo
Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values (NCT00742326)
Timeframe: 48 weeks
| Intervention | mg*120 minutes/dL (Mean) |
|---|
| Pioglitazone | -31 |
| Placebo | 11 |
Trials
1 trial available for pioglitazone and Co-infection